Rifaximin - A novel antimicrobial for enteric infections

Journal of Infection

Volumn 50, Issue 2, 2005, Pages 97-106

  Huang, David B ^a,b   DuPont, Herbert L ^a,b,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Bacterial diarrhea; Enteroaggregative E. coil; Enterotoxigenic; Rifamycin; Shigella sonnei; Travelers' diarrhea

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; FLONORM; NEBACETIN; PAROMOMYCIN; PLACEBO; REDACTIV; RIFACOL; RIFAMPICIN; RIFAXIMIN; SPIRAXIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZAXINE;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DNA BINDING; DRUG DOSE REGIMEN; DRUG FECES LEVEL; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; FATIGUE; FECES INCONTINENCE; FEVER; FLATULENCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; INTESTINE INFECTION; LIVER DYSFUNCTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; SHIGELLA SONNEI; TRAVELLER DIARRHEA; TREATMENT INDICATION; VOMITING;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; DIARRHEA; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; TRAVEL;

EID: 12444282737     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.05.019     Document Type: Article

References (62)

1. Jiang Z.D. Lowe B. Verenkar M.P. et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay) J Infect Dis 185 2002 497-502
2. Black R.E. Epidemiology of travelers' diarrhea and relative importance of various pathogens Rev Infect Dis 12 1990 S73-S79
3. Steffen R. Collard F. Tornieporth N. et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica JAMA 281 1999 811-817
4. von Sonnenburg F. Tornieporth N. Waiyaki P. et al. Risk and aetiology of diarrhoea at various tourist destinations Lancet 356 2000 133-134
5. Hyams K.C. Bourgeois A.L. Merrell B.R. et al. Diarrheal disease during operation desert shield N Engl J Med 325 1991 1423-1428
6. Reves R.R. Johnson P.C. Ericsson C.D. DuPont H.L. A cost-effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers' diarrhea Arch Intern Med 148 1988 2421-2427
7. DuPont H. Persistent diarrhea in a traveling student Gastrointest Dis Today 2 1993 1-6
8. Ilnyckyj A. Balachandra B. Elliott L. Choudhri S. Duerksen D.R. Post-traveler's diarrhea irritable bowel syndrome: A prospective study Am J Gastroenterol 98 2003 596-599
9. Okhuysen PC Jiang ZD Carlin L Forbes C DuPont HL. Frequency and characteristics of post infectious irritable bowel syndrome (IBS) in travelers to Mexico. 41st Annual Meeting of the Infectious Diseases Society of America 2003
10. Dworkin M.S. Shoemaker P.C. Goldoft M.J. Kobayashi J.M. Reactive arthritis and Reiter's syndrome following an outbreak of gastroenteritis caused by Salmonella enteritidis Clin Infect Dis 33 2001 1010-1014
11. Rees J.H. Soudain S.E. Gregson N.A. Hughes R.A. Campylobacter jejuni infection and Guillain-Barre syndrome N Engl J Med 333 1995 1374-1379
12. Guerrant R.L. Van Gilder T. Steiner T.S. et al. Practice guidelines for the management of infectious diarrhea Clin Infect Dis 32 2001 331-351
13. DuPont H.L. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology Am J Gastroenterol 92 1997 1962-1975
14. Gomi H. Jiang Z.D. Adachi J.A. et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions Antimicrob Agents Chemother 45 2001 212-216
15. Kuschner R.A. Trofa A.F. Thomas R.J. et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent Clin Infect Dis 21 1995 536-541
16. Smith K.E. Besser J.M. Hedberg C.W. et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team N Engl J Med 340 1999 1525-1532
17. Hoge C.W. Gambel J.M. Srijan A. Pitarangsi C. Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years Clin Infect Dis 26 1998 341-345
18. Adachi J.A. Ericsson C.D. Jiang Z.D. et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico Clin Infect Dis 37 2003 1165-1171
19. DuPont H.L. Ericsson C.D. Prevention and treatment of traveler's diarrhea N Engl J Med 328 1993 1821-1827
20. Hoover W.W. Gerlach E.H. Hoban D.J. Eliopoulos G.M. Pfaller M.A. Jones R.N. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative Diagn Microbiol Infect Dis 16 1993 111-118
21. Sierra J.M. Navia M.M. Vargas M. et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania J Antimicrob Chemother 47 2001 904-905
22. Lamanna A. Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria Chemioterapia 3 1984 365-367
23. Ripa S. Mignini F. Prenna M. Falcioni E. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp Drugs Exp Clin Res 13 1987 483-488
24. Marchese A. Salerno A. Pesce A. Debbia E.A. Schito G.C. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species Chemotherapy 46 2000 253-266
25. Musser J.M. Antimicrobial agent resistance in mycobacteria: Molecular genetic insights Clin Microbiol Rev 8 1995 496-514
26. Gionchetti P. Rizzello F. Ferrieri A. et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial Dig Dis Sci 44 1999 1220-1221
27. Descombe J.J. Dubourg D. Picard M. Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers Int J Clin Pharmacol Res 14 1994 51-56
28. Rizzello F. Gionchetti P. Venturi A. et al. Rifaximin systemic absorption in patients with ulcerative colitis Eur J Clin Pharmacol 54 1998 91-93
29. Jiang Z.D. Ke S. Palazzini E. Riopel L. Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration Antimicrob Agents Chemother 44 2000 2205-2206
30. DuPont H.L. Ericsson C.D. Mathewson J.J.et al. Rifaximin: A nonabsorbed antimicrobial in the therapy of travelers' diarrhea Digestion 59 1998 708-714
31. DuPont H.L. Jiang Z.D. Ericsson C.D. et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: A randomized, double-blind clinical trial Clin Infect Dis 33 2001 1807-1815
32. Steffen R. Sack D.A. Riopel L. et al. Therapy of travelers' diarrhea with rifaximin on various continents Am J Gastroenterol 98 2003 1073-1078
33. DuPont H.L. Cooperstock M. Corrado M.L. Fekety R. Murray D.M. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration Clin Infect Dis 15 1992 S228-S235
34. Beseghi U. De'Angelis G.L. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children Eur Rev Med Pharmacol Sci 2 1998 131-136
35. Frisari L. Viggiano V. Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea Curr Med Res Opin 14 1997 39-45
36. Corazza G.R. Ventrucci M. Strocchi A. et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin J Int Med Res 16 1988 312-316
37. Corazza G.R. Sorge M. Strocchi A. et al. Non-absorbable antibiotics and small bowel bacterial overgrowth Ital J Gastroenterol 24 1992 4-9
38. Cuoco L. Montalto M. Jorizzo R.A. et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics Hepatogastroenterology 49 2002 1582-1586
39. Karmali M.A. Petric M. Lim C. Fleming P.C. Arbus G.S. Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli J Infect Dis 151 1985 775-782
40. Giaccari S. Tronci S. Falconieri M. Ferrieri A. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon Riv Eur Sci Med Farmacol 15 1993 29-34
41. Gionchetti P. Rizzello F. Venturi A. et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis Aliment Pharmacol Ther 13 1999 713-718
42. Gruttadauria G. La Barbera F. Cutaia G. Salanitri G. Prevention of infection in colonic surgery by rifaximin. A controlled, prospective, randomized trial Riv Eur Sci Med Farmacol 9 1987 101-105
43. Latella G. Pimpo M.T. Sottili S. et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon Int J Colorectal Dis 18 2003 55-62
44. Miglio F. Valpiani D. Rossellini S.R. Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial Curr Med Res Opin 13 1997 593-601
45. Williams R. James O.F. Warnes T.W. Morgan M.Y. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double-blind, randomized, dose-finding multi-centre study Eur J Gastroenterol Hepatol 12 2000 203-208
46. DuPont H.L. Jiang Z.D. Influence of rifaximin treatment on susceptibility of intestinal Gram-negative flora and enterococci Clin Microbiol Infect Dis 2004
47. DeLeo C. Dftimiadi C. Schito G.C. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin Drugs Exp Clin Res 12 1986 979-981
48. Vosbeck K. Handschin H. Menge E.B. Zak O. Effects of subminimal inhibitory concentrations of antibiotics on adhesiveness of Escherichia coli in vitro Rev Infect Dis 1 1979 845-851
49. Riva S. Fietta A. Berti M. Silvestri L.G. Romero E. Relationships between curing of the F episome by rifampin and by acridine orange in Escherichia coli Antimicrob Agents Chemother 3 1973 456-462
50. Alexander W.J. Cobbs C.G. Curtiss R. III Modification of bacterial serum susceptibility by rifampin Infect Immun 28 1980 923-926
51. Soro O. Pesce A. Raggi M. Debbia E.A. Schito G.C. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin Clin Microbiol Infect 3 1997 147-151
52. Williams D.L. Spring L. Collins L. et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis Antimicrob Agents Chemother 42 1998 1853-1857
53. Yang B. Koga H. Ohno H. et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis J Antimicrob Chemother 42 1998 621-628
54. Lucchesi M. Marchi E. Venturini A.P. Antimycobacterial activity of rifaximin (L/105) in experimental tuberculosis in the guinea pig Chemioterapia 3 1984 371-372
55. Malvisi Stracciari J. Venturini A.P. Anfossi P. Marchi E. Stracciari G.L. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin Chemioterapia 6 1987 82-84
56. Di Stefano M. Strocchi A. Malservisi S. Veneto G. Ferrieri A. Corazza G.R. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms Aliment Pharmacol Ther 14 2000 1001-1008
57. Ericsson C.D. Johnson P.C. Dupont H.L. Morgan D.R. Bitsura J.A. de la Cabada F.J. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial Ann Intern Med 106 1987 216-220
58. DuPont H.L. Ericsson C.D. Mathewson J.J. DuPont M.W. Five versus three days of ofloxacin therapy for traveler's diarrhea: A placebo-controlled study Antimicrob Agents Chemother 36 1992 87-91
59. Di Piazza S. Gabriella Filippazzo M. Valenza L.M. et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy Ital J Gastroenterol 23 1991 403-407
60. De Giorgio R. Stanghellini V. Barbara G. Guerrini S. Ferrieri A. Corinaldesi R. Rifaximin and Helicobacter pyloli eradication Eur Rev Med Pharmacol Sci 1 1997 105-110
61. Megraud F. Bouffant F. Camou Juncas C. In vitro activity of rifaximin against Helicobacter pyroli Eur J Clin Microbiol Infect Dis 13 1994 184-186
62. Puxeddu A. Quartini M. Massimetti A. Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy Curr Med Res Opin 13 1995 274-281